NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $122.5 million in its fourth quarter.

On a per-share basis, the Novato, California-based company said it had a loss of $1.79.

The results fell short of Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.32 per share.

The biotechnology company posted revenue of $83.4 million in the period, also missing Street forecasts. Nine analysts surveyed by Zacks expected $84 million.

For the year, the company reported a loss of $454 million, or $6.70 per share. Revenue was reported as $351.4 million.

Ultragenyx expects full-year revenue in the range of $250 million to $260 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News